Milestone
Inhaled drug delivery specialists Vectura Group plc of Chippenham, UK, has announced that it has received a €2.5 million European milestone payment in relation to progress on the development of its combination asthma/chronic obstructive pulmonary disease product VR315.
Combination therapy for asthma and COPD is the biggest and fastest growing sector of the respiratory market, with annual sales currently exceeding $10 billion. VR315 is being developed as a generic product delivered with Vectura’s GyroHaler Dry Powder Inhaler delivery device. The company licensed the European rights for VR315 to Sandoz, the generics division of Novartis, in March 2006 and the US rights in December 2006.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
